About InnAVasc
InnAVasc is a Healthcare company based in Durham (United States) founded in 2013, and was acquired by W. L. Gore & Associates in August 2022. Synthetic vascular grafts with self-sealing chambers for hemodialysis are developed. InnAVasc has raised $3.34 million across 12 funding rounds from investors including W. L. Gore & Associates, Duke University and HHS. InnAVasc offers products and services including InnAVasc Arteriovenous Graft. Its focus areas include Life Sciences, Cardiac and Vascular Disorders, Medical Devices and Therapeutic Devices. Its legal entity is InnAVasc Medical, Inc. Its competitors include Cardival Medical, Saranas and Aziyo Biologics; 3 of its 3 listed competitors have raised funding.
Company details
InnAVasc Medical was founded in 2013 by Duke University surgeoninventors and is located in Durham, United States. Medical devices focused on vascular access for hemodialysis are designed and developed by the company. The initial product consists of a synthetic graft featuring two penetration-resistant chambers, one for outbound blood flow and one for inbound, each with self-sealing windows for needle punctures. FDA 510(k) clearance was granted in December 2014.
- Headquarters Durham, United States
- Stage Acquired
- SectorsHealthcare
- Website innavasc.com
- Social LinkedIn
- Acquired by W. L. Gore & Associates (Aug 2022)
- Legal Name Innavasc Medical, Inc.
- Total Equity Funding$3.34M (USD)
in 12 rounds
- Latest Funding Round$1M (USD), Debt – Conventional
Nov 2021
- InvestorsW. L. Gore & Associates
& 5 more
- Acquired byW. L. Gore & Associates
(Aug 2022)
Products & Services of InnAVasc
InnAVasc offers a comprehensive portfolio of products and services, including InnAVasc Arteriovenous Graft.
Reduces complications and bleeding during hemodialysis treatments.
Funding Insights of InnAVasc
InnAVasc has successfully raised a total of $3.34M across 12 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $1 million completed in November 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $3.34M
- Total Rounds 12
- Last Round Debt – Conventional — $1M
- Investors Count 5
Latest 10 of 12 funding rounds of InnAVasc with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2021 | $1M | Debt – Conventional | – | – | – |
| Apr 2020 | $414,501 | Debt – Conventional | – | – | – |
| Apr 2020 | $799,943 | Grant | – | – | |
| Feb 2019 | $224,975 | Grant | – | – | |
| Dec 2018 | $500,000 | Debt – Conventional | – | – | |
| Oct 2018 | $500,000 | Series A | – | – | – |
| Nov 2016 | $2.15M | Series A | – | – | – |
| Sep 2016 | $5.15M | Grant | – | – | |
| Apr 2016 | $520,000 | Debt – Conventional | – | – | – |
| Jun 2015 | $695,000 | Seed | – | MedBlue Incubator | – |
6 investors in total: 6 institutional.
Investors in InnAVasc
InnAVasc has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include W. L. Gore & Associates, Duke University and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital fund backed by the US Government | seedfund.nsf.gov | Alexandria, United States | ||
Biotech startups are incubated and funded in North Carolina. | 1984 | ncbiotech.org | Durham, United States | |
| medblueincubator.com | ||||
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
Multiple courses and degrees across diversified streams are offered. | 1838 | duke.edu | United States | |
A portfolio of material science-based products is developed. | 1958 | gore.com | Newark, United States |
Investor details for InnAVasc
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of InnAVasc
1 people are tracked at InnAVasc (1 in leadership).
| Name | Role | Group |
|---|---|---|
Roberto Manson, MD | Founder | Leadership |
Complete people profiles for InnAVasc
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of InnAVasc
4 dated milestones of InnAVasc across 9 years, from founding to its latest funding, stage changes and deals.
- Founded InnAVasc is founded.
- Funding First funding round.
- Funding Latest funding round, Debt – Conventional, of $1.0M.
- Exit Acquired by W. L. Gore & Associates.
Competitors of InnAVasc
InnAVasc has 3 listed competitors in our database, 3 of them funded. They include Cardival Medical, Saranas and Aziyo Biologics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| cardivamedical.com | 2002 | Santa Clara, United States | $169.45M | 158 | A device for vascular access management is developed. | |
| saranas.com | 2011 | Houston, United States | $29.46M | A device is developed for detecting internal bleeding during catheterization. | ||
| aziyo.com | 2015 | Silver Spring, United States | $49.59M | 162 | Regenerative medicine products are developed for orthopedic and cardiovascular applications. |
Detailed competitors of InnAVasc
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Cardiac and Vascular Disorders
3 companies that operate in the same segment as InnAVasc (Cardiac and Vascular Disorders) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Gene-editing therapies for coronary artery disease are developed. | 2018 | Cambridge, Massachusetts, United States | USD 215.5 M | 255 | ||
Cardiac monitoring devices and applications are provided for heart health. | 2010 | Mountain View, California, United States | USD 114.38 M | USD 6.18 M | 67 | |
Therapies for lowering low-density lipoprotein cholesterol levels are developed. | 1998 | Ann Arbor, Michigan, United States | USD 129.7 M | USD 332.31 M | 304 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Innavasc
Complete news archive for InnAVasc
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about InnAVasc
InnAVasc was founded in 2013 and raised its 1st funding round 1 year after it was founded.
InnAVasc is headquartered in Durham, United States. It is registered at Durham, North Carolina, United States.
InnAVasc is a funded company, having raised a total of $3.34M across 12 funding rounds to date. The company's 1st funding round was a Seed of $695K, raised on Oct 2014.
InnAVasc Medical was founded in 2013 by Duke University surgeoninventors and is located in Durham, United States. Medical devices focused on vascular access for hemodialysis are designed and developed by the company. The initial product consists of a synthetic graft featuring two penetration-resistant chambers, one for outbound blood flow and one for inbound, each with self-sealing windows for needle punctures. FDA 510(k) clearance was granted in December 2014.
InnAVasc's top competitors include Cardival Medical, Aziyo Biologics and Saranas.
InnAVasc offers InnAVasc Arteriovenous Graft.
InnAVasc has 6 investors. Key investors include W. L. Gore & Associates, Duke University, HHS, NCBiotech, and America’s Seed Fund.
InnAVasc operates through Innavasc Medical, Inc..
Yes. InnAVasc was acquired by W. L. Gore & Associates in August 2022.